Veracyte Downgraded to 'Hold' by Zacks Research

Analysts cite concerns over the company's recent price target reduction and market performance.

Mar. 14, 2026 at 11:07am

Got story updates? Submit your updates here. ›

Veracyte (NASDAQ:VCYT), a genomic diagnostics company, has been downgraded from a 'strong-buy' rating to a 'hold' rating by Zacks Research. This comes after Morgan Stanley cut the company's price target from $48 to $37, citing market challenges. Veracyte's stock has seen volatility in recent months, trading between a 52-week low of $22.61 and a high of $50.71.

Why it matters

Veracyte's downgrade by a prominent research firm like Zacks could impact investor sentiment and the company's stock performance in the near term. As a leader in genomic diagnostics, Veracyte's market position and ability to navigate industry challenges will be closely watched by investors and analysts.

The details

Zacks Research cited the recent price target reduction by Morgan Stanley as a key factor in their decision to downgrade Veracyte. Morgan Stanley had lowered its price target for the company from $48 to $37, citing market headwinds. Veracyte's stock has seen significant volatility, trading in a wide range over the past 52 weeks.

  • Veracyte was downgraded by Zacks Research on Thursday, March 14, 2026.
  • Morgan Stanley reduced its price target for Veracyte on Thursday, March 5, 2026.

The players

Zacks Research

A prominent equity research firm that provides investment research and analysis to institutional and individual investors.

Veracyte

A genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing.

Morgan Stanley

A global financial services firm that provides investment banking, securities, wealth management and investment management services.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

Veracyte's downgrade by Zacks Research highlights the volatility and challenges facing the genomic diagnostics industry, as companies navigate market headwinds and investor sentiment. The company's ability to maintain its market position and financial performance will be closely watched in the coming months.